This week in therapeutics

Indication	Target/marker/ pathway	Summary	Licensing status	Publication and contact information
Cancer				
Non-small cell lung cancer (NSCLC)	Lactate dehydrogenase A (LDHA); K-Ras (KRAS); epidermal growth factor receptor 1 (EGFR1; HER1; ErbB1)	<p>Mouse studies suggest inhibiting LDHA could help treat <i>KRAS</i>- and <i>EGFR1</i>-mutant NSCLC. LDHA catalyzes a key step in anaerobic glycolysis, which NSCLC relies upon for growth and metastasis. In normal mice, injection of a human <i>KRAS</i>-mutant NSCLC cell line expressing an <i>LDHA</i> shRNA resulted in fewer metastatic lesions than injection of unmodified cells. In mice with NSCLC xenograft tumors harboring activating mutations in <i>KRAS</i> or <i>EGFR1</i>, <i>Ldha</i> deficiency decreased glycolytic metabolite levels and tumor growth compared with unmodified <i>Ldha</i> expression. Results of <i>Ldha</i> deficiency in other tumor types will be reported in an upcoming publication.</p> <p>SciBX 7(17); doi:10.1038/scibx.2014.492 Published online May 1, 2014</p>	Unpatented; licensing status not applicable	<p>Xie, H. <i>et al. Cell Metab.</i>; published online April 10, 2014; doi:10.1016/j.cmet.2014.03.003 Contact: Pankaj Seth, Beth Israel Deaconess Medical Center, Boston, Mass. e-mail: pseth@bidmc.harvard.edu Contact: Teresa W.M. Fan, University of Louisville, Louisville, Ky. e-mail: teresa.fan@uky.edu</p>